Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The experimental long-acting injectable regimen of cabotegravir and rilpivirine stands poised for approval.
Given every four weeks, the combo injection of cabotegravir and Edurant (rilpivirine) will likely face an FDA decision by early 2020.
The trial will investigate whether injections of long-acting cabotegravir and rilpivirine yield a superior rate of viral suppression.
Dosed every four weeks, the injection, which requires a clinic visit, includes long-acting rilpivirine and cabotegravir.
The Conference on Retroviruses and Opportunistic Infections in Seattle saw many important studies that are advancing the fight against HIV.
Participants in a study were started on daily oral drugs and then half were switched over to long-acting meds.
Given every four weeks, combo injections of cabotegravir and rilpivirine will likely face an FDA decision by early 2020.
Promising findings from a study of a two-drug injectable treatment given every four weeks.
The company has released new data from a trial of injectable cabotegravir and Edurant given every four or eight weeks.
ViiV Healthcare has reported promising one-year findings from a study of a two-drug injectable treatment given every four weeks.
Researchers presented 100-week data on a trial of the antiretroviral (ARV) regimen at the international AIDS conference.
In a recent study, Edurant was better tolerated and less toxic and led to fewer discontinuations.
Juluca is a single-tablet regimen for HIV.
HIV-positive members of a recent study saw many upsides to getting injections of meds only every four or eight weeks.
The single-tablet regimen contains ViiV’s integrase inhibitor dolutegravir and Janssen’s NNRTI rilpivirine.
ViiV Healthcare has applied to the FDA for approval of the first two-drug antiretroviral (ARV) regimen to treat HIV.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.